Publications by authors named "Michallet M"

Although senescent cells can be eliminated by the immune system, they tend to accumulate with age in various tissues. Here we show that senescent cells can evade immune clearance by natural killer (NK) cells by upregulating the expression of the disialylated ganglioside GD3 at their surface. The increased level of GD3 expression on senescent cells that naturally occurs upon aging in liver, lung, kidney or bones leads to a strong suppression of NK-cell-mediated immunosurveillance.

View Article and Find Full Text PDF

This article describes some of the key prevention services in the Leon Berard Comprehensive Cancer Center (CLB) Lyon, France, which are based on clinical prevention services, outreach activities, and collaboration with professional and territorial health communities. In addition, research is embedded at all stages of the prevention continuum, from understanding cancer causes through to the implementation of prevention interventions during and after cancer. Health promotion activities in the community and dedicated outpatient primary cancer prevention services for individuals at increased risk have been implemented.

View Article and Find Full Text PDF

Background & Objectives: The primary objective of this observational study was to perform an exhaustive description concerning patients receiving extracorporeal photopheresis (ECP) as second line treatment after steroid resistance for either acute or chronic GVHD following allo-HCT, secondary objectives were to evaluate the efficacy and long-term outcomes.

Study Design: A total of 106 patients were included, 65 (61%) males and 41 (39%) females with a median age at transplantation of 52 years (range: 20-67). ECP was initiated after transplantation either for acute GVHD [N = 25 (24%), 12 grade III and 13 grade IV] affecting skin alone (N = 5), gut alone (N = 12), gut and liver (N = 8), or chronic GVHD [N = 81 (76%), 15 (14%) limited and 66 (62%) extensive].

View Article and Find Full Text PDF

Background: Venetoclax (VNX)-based regimens have demonstrated significantly favorable outcomes in patients with acute myeloid leukemia (AML) and are now becoming the standard treatment. Tyrosine kinase inhibitors are administered at a fixed dose, irrespective of body surface area or weight. For such orally targeted therapies, real-world data have highlighted a larger pharmacokinetic (PK) interindividual variability (IIV) than expected.

View Article and Find Full Text PDF

Breast cancer is one of the most prominent types of cancers, in which therapeutic resistance is a major clinical concern. Specific subtypes, such as claudin-low and metaplastic breast carcinoma (MpBC), have been associated with high nongenetic plasticity, which can facilitate resistance. The similarities and differences between these orthogonal subtypes, identified by molecular and histopathological analyses, respectively, remain insufficiently characterized.

View Article and Find Full Text PDF

Over 90% of epidemic non-bacterial gastroenteritis are caused by human noroviruses (NoVs), which persist in a substantial subset of people allowing their spread worldwide. This has led to a significant number of endemic cases and up to 70,000 children deaths in developing countries. NoVs are primarily transmitted through the fecal-oral route.

View Article and Find Full Text PDF

Background: t-AML occurs after a primary malignancy treatment and retains a poor prognosis.

Aims: To determine the impact of primary malignancies, therapeutic strategies, and prognostic factors on clinical outcomes of t-AML.

Results: A total of 112 adult patients were included in this study.

View Article and Find Full Text PDF

Graft failure has remained a limitation of umbilical cord blood transplantation (CBT). Here, we assessed the outcomes of patients who experienced graft failure after CBT. Inclusion criteria were patients (age ≥ 18 years) experiencing graft failure after unrelated CBT (single or double) between 2005 and 2016, for acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL), no prior allogeneic or autologous transplantation, no other stem cell product.

View Article and Find Full Text PDF

Malignant pleural mesothelioma (MPM) is an aggressive cancer with rising incidence and challenging clinical management. Through a large series of whole-genome sequencing data, integrated with transcriptomic and epigenomic data using multiomics factor analysis, we demonstrate that the current World Health Organization classification only accounts for up to 10% of interpatient molecular differences. Instead, the MESOMICS project paves the way for a morphomolecular classification of MPM based on four dimensions: ploidy, tumor cell morphology, adaptive immune response and CpG island methylator profile.

View Article and Find Full Text PDF

Background: Recently, the combination of venetoclax plus a hypomethylating agent (HMA; azacitidine ordecitabine) or low-dose cytarabine (LDAC) showed promise in Phase III trials in previously untreated AML. In France at the time of this study, venetoclax was not yet approved for AML and there were therefore no formal usage recommendations. Here we report the first study in a French cohort that assessed venetoclax in combination with existing treatments for AML under real-life conditions.

View Article and Find Full Text PDF

Subsequent neoplasms (SNs) compromise long-term survivors after hematopoietic cell transplantation. We performed a retrospective analysis of SNs in 10 358 recipients of umbilical cord blood transplantation (UCBT) from 1988 to 2018. SNs developed in 233 patients and 84 were of pediatric age.

View Article and Find Full Text PDF

The surface of the central nervous system (CNS) is protected by the meninges, which contain a dense network of meningeal macrophages (MMs). Here, we examined the role of tissue-resident MM in viral infection. MHC-II MM were abundant neonatally, whereas MHC-II MM appeared over time.

View Article and Find Full Text PDF
Article Synopsis
  • The study analyzed the incidence and characteristics of therapy-related myeloid neoplasms (t-MN) in ovarian cancer patients treated with PARP inhibitors (PARPi) at a French cancer center.
  • Out of 373 patients with ovarian cancer under PARPi treatment, 3.5% developed t-MN, showing longer treatment duration and more severe cytopenias compared to those without t-MN.
  • Key findings indicated a high frequency of BRCA1/2 mutations in t-MN patients exposed to PARPi, and the presence of complex karyotypes linked to poor overall survival, highlighting the need for early detection of this complication.
View Article and Find Full Text PDF
Article Synopsis
  • Allogeneic hematopoietic stem cell transplantation (allo-HSCT) using FLAMSA-Bu is a treatment option for high-risk acute myeloid leukemia (AML) patients, particularly those who are refractory or have relapsed.
  • A study of 165 patients showed that detectable minimal residual disease (MRD) before transplantation was linked to worse overall survival (OS) and higher relapse rates following the procedure.
  • The findings highlight that pre-transplant MRD status is a crucial indicator of patient outcomes, with MRD negativity correlated to better survival and reduced relapse risk, while factors such as age and risk stratification did not significantly impact outcomes.
View Article and Find Full Text PDF

Background: Invasive fungal diseases (IFD) remain a major complication of allogeneic hematopoietic stem cell transplantation (alloHSCT) and are associated with high mortality rates in patients receiving alloHSCT. Antifungal prophylaxis is increasingly being used in the management of IFDs in patients receiving alloHSCT.

Methods: A post-hoc analysis of the cross-sectional observational AFHEM study was carried out to describe the use of antifungal drugs in real-life clinical practice in alloHSCT recipients hospitalized in French hematological units.

View Article and Find Full Text PDF
Article Synopsis
  • Platelets interact with neutrophils to form neutrophil-platelet aggregates (NPAs), which enhance neutrophil functions during inflammation and may worsen various inflammatory diseases, including cancer.
  • Research using advanced imaging techniques revealed that NPAs are primarily formed through platelets binding to low-density neutrophils (LDNs) in both healthy individuals and cancer patients.
  • Analyzing the genetic profile of NPAs indicated a unique molecular signature linked to neutrophil activation and worse prognosis in cancer patients, suggesting NPAs could serve as a valuable noninvasive biomarker for monitoring cancer progression.
View Article and Find Full Text PDF

While in vivo T-cell depletion (TCD) is widely used, its benefit in patients with MDS still remains a matter of debate. This study evaluates the impact of TCD on outcomes, and compares ATG and alemtuzumab, in patients with MDS. 1284 patients from the EBMT registry were included in this study with 470 patients in the no-TCD group and 814 in the TCD group (alemtuzumab N = 168; ATG N = 646).

View Article and Find Full Text PDF
Article Synopsis
  • The study examines the real-world use of antifungal prophylaxis (AFP) in patients with acute myeloblastic leukaemia (AML) after they receive induction chemotherapy, highlighting variations across different treatment centers.
  • Out of 677 patients, four AFP strategies were identified, with the group receiving no prophylaxis having the highest incidence of invasive fungal infections (IFI) and a significantly earlier onset compared to those on posaconazole.
  • AFP was found to delay the onset of IFIs and reduce their overall occurrence; however, misidentification of IFIs by investigators affects treatment management, impacting overall patient outcomes and rate of complete remission in AML.
View Article and Find Full Text PDF
Article Synopsis
  • The study examines outcomes of adolescents and young adults with acute myeloid leukemia (AML) after receiving their first allogeneic hematopoietic stem cell transplant (HSCT) from 2005 to 2017.
  • Results showed a median follow-up of 4.37 years, revealing varying 2-year overall survival rates: 71.4% for children, 61.1% for adolescents and post-adolescents, and 62.9% for young adults, with significant differences in relapse and non-relapse mortality.
  • Key risk factors for death identified include the patient's AML cytogenetics, disease status at transplant, use of total body irradiation, and graft source, highlighting the need for tailored treatments
View Article and Find Full Text PDF

Introduction: Older adults with cancer suffer from the combined effects of ageing, cancer disease and treatment side effects. The main treatment for patients with haematological malignancies is chemotherapy, associated with significant toxicities. Chemotherapy can alter patients' physical function and quality of life which are often already diminished in older patients due to ageing and comorbidities.

View Article and Find Full Text PDF

Acute myeloid leukemia (AML) intensive chemotherapy combined with broad-spectrum antibiotics, leads to gut microbiota dysbiosis promoting pathological conditions and an increased incidence of complications. Here we report findings from a phase II single-arm, multicenter study evaluating autologous fecal microbiota transfer (AFMT) in 25 AML patients treated with intensive chemotherapy and antibiotics (ClinicalTrials.gov number: NCT02928523).

View Article and Find Full Text PDF
Article Synopsis
  • Breast cancer significantly impacts women both physically and mentally, leading to long-lasting effects after diagnosis.
  • A study involving 654 women in France examined the changes in treatment side effects and associated factors two and five years post-diagnosis, highlighting six main categories of ongoing issues.
  • Findings revealed that while fatigue decreased over time, cognitive problems increased, indicating a need for improved patient care strategies to support women at risk for persistent sequelae.
View Article and Find Full Text PDF

Objectives: Secondary antibody deficiency (SAD), associated with severe, recurrent or persistent infections, is common in patients with haematological malignancies (HM), but unifying guidance on immunoglobulin replacement therapy (IgRT) in these patients is lacking. We aimed to develop consensus statements for the use of IgRT in patients with HM.

Methods: A Delphi exercise was employed to test the level of agreement on statements developed by a Task Force based on available data and their clinical experience.

View Article and Find Full Text PDF